Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
16 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
2ans d'exercice (thèse 2024)·28 publications sur 5 ans
✨ Génération du profil synthétique IA en cours…
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
14
14 articles ont été cités au moins 14fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
566
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
49
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
19
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Louis-Mourier
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Consensus on the Management of Anesthetic Agents During Digestive Motility Measurements and Proposal of a Standardized Protocol for Anesthesia (French Neuro Gastroenterology Group GFNG and Committee of Anesthetic French Experts)
2025ArticleNeurogastroenterology & Motility
Empowering the Next Generation of Neurogastroenterology—Welcome yESNM
2025ArticleNeurogastroenterology & Motility
Constipation induite par les opioïdes : état des lieux et modalités de prise en charge
2025ArticleBulletin du Cancer
Efficacy of gastric per-oral endoscopic myotomy remains similar after failure of interventional techniques in refractory gastroparesis
2024ArticleClinics and Research in Hepatology and Gastroenterology
Apport de la manométrie antro-pyloro-duodénale haute résolution couplée à l'impédancemétrie dans la physiopathologie des syndromes dyspeptiques.
2024Thèse
Alterations in gastrointestinal motility assessed by high-resolution antroduodenal manometry in patients with severe disorders of gut-brain interaction
2024ArticleAJP - Gastrointestinal and Liver Physiology
Correction: Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2024ArticleGenome Medicine
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
2023ArticleGenome Medicine
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP NUP SITE LOUIS MOURIER
178 R DES RENOUILLIERS, 92701 COLOMBES CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Scientific reports · 2021
AbstractSynthetized by the liver and metabolized by the gut microbiota, BA are involved in metabolic liver diseases that are associated with cardiovascular disorders. Animal models of atheroma documented a powerful anti-atherosclerotic effect of bile acids (BA). This prospective study examined whether variations in circulating BA are predictive of coronary artery disease (CAD) in human. Consecutive patients undergoing coronary angiography were enrolled. Circulating and fecal BA were measured by high pressure liquid chromatography and tandem mass spectrometry. Of 406 screened patients, 80 were prospectively included and divided in two groups with (n = 45) and without (n = 35) CAD. The mean serum concentration of total BA was twice lower in patients with, versus without CAD (P = 0.005). Adjusted for gender and age, this decrease was an independent predictor of CAD. In a subgroup of 17 patients, statin therapy doubled the serum BA concentration. Decreased serum concentrations of BA were predictors of CAD in humans. A subgroup analysis showed a possible correction by statins. With respect to the anti-atherosclerotic effect of BA in animal models, and their role in human lipid metabolism, this study describe a new metabolic disturbance associated to CAD in human.
Brain sciences · 2021
Patients with Parkinson disease (PD) experience a range of non-motor symptoms, including gastrointestinal symptoms. These symptoms can be present in the prodromal phase of the disease. Recent advances in pathophysiology reveal that α-synuclein aggregates that form Lewy bodies and neurites, the hallmark of PD, are present in the enteric nervous system and may precede motor symptoms. Gastroparesis is one of the gastrointestinal involvements of PD and is characterized by delayed gastric emptying of solid food in the absence of mechanical obstruction. Gastroparesis has been reported in nearly 45% of PD. The cardinal symptoms include early satiety, postprandial fullness, nausea, and vomiting. The diagnosis requires an appropriate test to confirm delayed gastric emptying, such as gastric scintigraphy, or breath test. Gastroparesis can lead to malnutrition and impairment of quality of life. Moreover, it might interfere with the absorption of antiparkinsonian drugs. The treatment includes dietary modifications, and pharmacologic agents both to accelerate gastric emptying and relieve symptoms. Alternative treatments have been recently developed in the management of gastroparesis, and their use in patients with PD will be reported in this review.
United European gastroenterology journal · 2019
Background and aimsSteroid therapy is the first‐line treatment for autoimmune pancreatitis but relapses are frequent. The aims were to assess the efficacy and the safety of immunomodulator treatments for relapsing autoimmune pancreatitis and rituximab in particular and to identify relapsing risk factors.MethodsPatients followed for autoimmune pancreatitis from 2000 to 2016 were included. Data were retrospectively analysed regarding autoimmune pancreatitis treatment.ResultsIn total, 162 patients with autoimmune pancreatitis type 1 (n = 92) and type 2 (n = 70) were included (median follow‐up: 3 years (0.5–14). Relapse occurred in 46.5% of patients with autoimmune pancreatitis type 1 (vs 19.3% in autoimmune pancreatitis 2; p < 0.001). Risk factors of relapse were cholangitis, initial use of steroids, other organ involvement and chronic pancreatitis in autoimmune pancreatitis type 1 and initial use of steroids, tobacco consumption and chronic pancreatitis for autoimmune pancreatitis type 2. Overall, 21 patients were treated with immunomodulators (azathioprine, n = 19, or methotrexate, n = 2) for relapses. The efficiency rate was 67%. A total of 17 patients were treated with rituximab, with two perfusions at 15 days apart. The efficacy was 94% (16/17), significantly better than immunomodulator drugs (p = 0.03), with a median follow‐up of 20 months (11–44). Only two patients needed two supplementary perfusions.ConclusionIn relapsing autoimmune pancreatitis, rituximab is more efficient than immunomodulator drugs and shows better tolerance.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European radiology · 2024 · Journal Article
Soliman S, Soliman H, Crézé M, Brillet PY, et al.
Neurogastroenterology and motility · 2023 · Journal Article
Soliman H, Schalla MA, Coffin B, Gourcerol G
Neurogastroenterology and motility · 2023 · Observational Study
Gourcerol G, Gonzalez JM, Bonaz B, Fontaine S, et al.
Scientific reports · 2021 · Journal Article
Chong Nguyen C, Duboc D, Rainteau D, Sokol H, et al.
Brain sciences · 2021 · Journal Article
Soliman H, Coffin B, Gourcerol G
International orthopaedics · 2020 · Journal Article
Abdelaziz AM, Aldahshan W, Elsherief FAH, Wahd YESH, et al.
Italian journal of pediatrics · 2024 · Journal Article
Shamma RA, Soliman HM, Abdelfattah W, Badawy MA, et al.
Pediatric rheumatology online journal · 2023 · Journal Article
Soliman HM, Fahmy BS, Ali MG, Shafie ES
Endoscopy international open · 2026 · Journal Article
Marcellier G, Hedjoudje A, Jais B, Maire F, et al.
Surgical endoscopy · 2022 · Journal Article
Soliman H, Oiknine E, Cohen-Sors B, Moszkowicz D, et al.
United European gastroenterology journal · 2019 · Comparative Study
Soliman H, Vullierme MP, Maire F, Hentic O, et al.
Diabetes & metabolism · 2023 · Letter
Phan F, Halbron M, Jacqueminet S, Popelier M, et al.
BMC complementary and alternative medicine · 2016 · Journal Article
Hozayen WG, El-Desouky MA, Soliman HA, Ahmed RR, et al.
Neurogastroenterology and motility · 2026 · Journal Article
Renard D, Clavier T, Abou-Arab O, Amarenco G, et al.
Bulletin du cancer · 2025 · English Abstract
Boilève A, Desprez C, Scotté F, Coffin B, et al.
United European gastroenterology journal · 2018 · Journal Article
Soliman H, Brieau B, Guillaumot MA, Leblanc S, et al.
Supplementary Table 2 HRADM GP
Supplementary table 2 for article "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry</b>"
Supplementary Tables HRADM Gastroparesis
Supplementary tables 2 for article "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry</b>"
Supplementary Table 2 Mano GP.docx
Supplementary tables 2 for article "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry</b>"
Supplementary Table 1 HRADM GP
Supplementary Table 1 for "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry"</b>
Supplementary Table 2 HRADM GP
Supplementary table 2 for article "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry</b>"
Supplementary Table 2 HRADM Gastroparesis
Supplementary table 2 for article "<b>Physiologic characterization of gastric emptying with high-resolution antropyloroduodenal manometry</b>"
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).